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Summary
The human immunodeficiency virus (HIV) type-1 is a
human-specific virus. The lack of a widely available small-
animal model has seriously hampered HIV research. In
2004, a new humanised mouse model was reported. It was
based on the intrahepatic injection of human CD34+ cord
blood cells into newborn, highly immunodeficient mice.
These mice develop a lymphoid system of human origin
and are highly susceptible to HIV infection and showed
disseminated infection, persistent viraemia and character-
istic helper CD4+ T-cell loss. Here, we will briefly review
the various existing humanised mouse models and high-
light their value to the study of HIV infection.
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The HIV situation globally
The UNAIDS report on the Global AIDS Epidemic 2010
optimistically announced that the HIV pandemic had
peaked in the preceding two years. Nevertheless, the num-
bers are shocking: an estimated 33.3 million humans –
0.8% of all adults 15–49 years old – are infected, and
more than 1.8 million people died in 2009 (ht-
tp://www.unaids.org/globalreport/Global_report.htm).
More hopefully, the number of people newly infected with
HIV declined by nearly one-fifth over the last decade
(1999, 3.1 million; 2009, 2.6 million). This decline is based
on more widely applied “safer sexual practices” and reduc-
tions in mother-child transmission. The UNAIDS vision is
Zero New Infections, Zero Discrimination, Zero HIV-asso-
ciated Deaths. The goal is to halt and reverse the spread of
HIV.
A human-specific virus: a challenge
for in vivo studies
HIV specifically infects human cells. Even cells from
chimpanzee, a very close relative of humans, are only
somewhat permissive to HIV infection [1]. Human host
factors are critical for the virus throughout its entire replic-
ation cycle (fig. 1). For example, to enter a cell and begin
its replication cycle, HIV engages a receptor complex of
CD4 and a chemokine receptor, either CCR5 or CXCR4
[2, 3]. However, expressing human CD4 on murine cells
does not make them permissive to HIV. Other human-spe-
cific factors, such as the human chemokine receptors, are
needed.
Over the last three decades, human transgenes essential for
HIV replication were expressed together in rodent cells, but
the cells were still not permissive [4]. Furthermore, human
transgenes were expressed in rodents in an attempt to gen-
erate HIV small-animal models. These models confirmed
the human-specific nature of HIV and the in vitro data. No
replication was observed in mice expressing human CD4
[5], CD4 and CCR5 [6] and Cyclin CDK9 [7], and rats
transgenic for human CD4 and CCR5 replicated HIV only
at very low levels for limited times [8, 9].
Other in vivo studies attempted to create models based on
creating chimeric HIV strains. This approach relies on en-
gineering a distinct HIV gene in a species-specific retrovir-
us, which despite the HIV transgene, replicates vigorously
in the original species (e.g., simian-immunodeficiency vir-
us [SIV] engineered to express the HIV envelope [SHIV])
[10]. The use of SHIV in monkeys allowed key questions
about immune responses to vaccine constructs expressing
various HIV gene encoded proteins to be addressed [10].
However, use of monkeys as animal models is restricted to
specific questions with a narrow focus and cannot recapit-
ulate the overall complexity of HIV, since the biological
properties between SHIV, SIV and HIV are quite distinct.
Finally, HIV-encoded gene products were expressed en-
tirely as transgenes in mice [11–15]. These studies
provided insight into the pathogenic potential of HIV gene
products. However, they were expressed universally at high
levels, and it is difficult to assess the significance of the res-
ulting data since the dynamic nature of true HIV replication
is lacking.
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The requirements for a mouse model
to study HIV infection
Faithfully modelling any human disease in an animal is dif-
ficult. Does the model replicate enough key features of the
disease to allow us to conduct experiments?
Many of the key features of HIV infection are known. The
main route of HIV transmission is vaginal or rectal inter-
course. In acute HIV infection, a massive productive infec-
tion causes cell death in the lymphatic system, most prom-
inently in the gastrointestinal tract. About 3–5 weeks after
acute HIV infection, the levels of HIV RNA decline and
the specific anti-HIV CD8+ T-cell response begins. Un-
like in acute infection, fewer than 1% of CD4+ T cells
are productively infected in the chronic phase [16], a num-
ber that cannot fully explain the progressive immunodefi-
ciency. Poorly understood bystander effects seem to con-
tribute to the overall cell loss [17], and sustained immune
activation triggers it [18]. Combined antiretroviral treat-
ment (cART) has been very successful in suppressing HIV
RNA levels to below the limit of detection in about 90% of
treated patients [19] and has resulted in a marked reduction
of morbidity and mortality [20]. However, cART does not
cure HIV. A small portion of HIV remains silent in long-
lived cells, such as the quiescent memory CD4+ T-cells
[21]; these cells form a latent reservoir of HIV. Besides
finding simpler and more efficient treatment strategies, ma-
jor efforts are now aimed at eradicating the latently infected
cells to eventual cure HIV, and to develop novel gene ther-
apy approaches and vaccination strategies. Other efforts are
focused on orally administered pre-exposure prophylactic
measures using anti-retroviral drugs and finding effective
topical microbicides that can prevent sexual transmission.
Thus, the requirements for a HIV mouse model include the
following:
– Permissiveness to replication-competent HIV with
distinct co-receptor usage (i.e., CCR5- or
CXCR4-tropic HIV strains), resulting in high-level
viraemia, systemic viral dissemination and
histopathology reminiscent of HIV disease in humans.
– Supporting long-term chronic infection, allowing
monitoring of HIV infection over time.
– Susceptibility to natural transmission modes of HIV,
including vaginal and rectal routes.
– Displaying gradual depletion of CD4+ T-cell numbers
during HIV infection.
– Activation of the immune system to lead to HIV-
specific immune responses.
– Establishment and maintenance of an HIV latent
reservoir.
– Allow development and testing of anti-HIV therapeutic
and prevention strategies.
Humanised mice in general
The generation of humanised mice involves either the ex-
pression of human transgenes or the transplantation of hu-
man tissue into immunodeficient mice. However, as men-
tioned above, even constitutive expression of multiple hu-
man transgenes has not rendered mice fully permissive to
HIV infection.
The human-PBL-SCID and foetal thy/liv SCID mouse
model
Transplantation of human tissue into immunodeficient
mice without rejection was first reported in the early 1980s.
This became possible with the identification of a spontan-
eous mutation of the Prkdc gene in mice, which results in
the complete lack of T and B cells and consequently in
severe combined immunodeficiency (C.B.-17 SCID/SCID
[SCID]; descriptions of the various mouse strains, see box)
[22]. The Prkdc gene encodes for the catalytic subunit of
a DNA-dependent protein kinase that is needed for V(D)J
recombination in developing T and B lymphocytes. The
two early humanised (Hu) mouse models were the foetal
thymus/liver (thy/liv) SCID-hu mouse [23, 24] and the hu-
PBL-SCID (PBL, peripheral blood leucocytes) mouse [25].
The foetal thy/liv SCID-hu mouse model is based on sur-
gical placement of foetal thymus/liver tissue under the ren-
al capsule. At 4–6 months post-implantation, foetal
thymus/liver tissue forms a conjoint organoid that re-
sembles human thymus and sustains T-cell lymphopoiesis
for over a year [23]. The system is susceptible to HIV in-
fection, but in the absence of robust peripheral human leuk-
ocyte reconstitution, samplings to analyse the infected hu-
man cells are mainly restricted to the engrafted conjoint or-
ganoid. Also there is no multilineage human haematopoies-
is in this model (table 1).
Figure 1
HIV-1 needs critical host factors for efficient replication. HIV binds to the HIV receptor
complex of the human CD4 cell-surface molecule and a co-receptor, either CCR5 or
CXCR4, via the HIV envelope glycoprotein 120 (HIV env gp120). After conformational
changes in the HIV env gp41, viral host cell membrane fusion occurs (2). The next steps
are the decapsidation (3) and release of the HIV RNA from the virus particle. Reverse
transcription generates a viral complementary DNA (cDNA) based on the viral RNA
template and using HIV’s own reverse transcriptase (4). Once the cDNA is generated, the
preintegration complex (PIC) is assembled, nuclear trafficking and integration of the viral
cDNA into the host genomic DNA follow (5). Efficient transcription and elongation require
formation of P-TEFb (positive transcription elongation factor b) consisting of Tat (6A),
human cyclin-dependent kinase 9 (CDK-9) (6B) and cyclin T1 (6C), which binds to the
nascent HIV transcripts. Fully or partially spliced HIV mRNA (7) is used to translate viral proteins. Unspliced HIV RNA is packaged into newly
generated virions. Assembly of HIV proteins and RNA and budding takes place at the cellular membrane (9). HIV release is inhibited by murine
tetherin at the cellular membrane because murine tetherin is insensitive to the viral protein Vpu, which inhibits human tetherin by directing its
proteasomal degradation (blue frame). Human host factors critical for HIV replication are CD4, CCR5, CXCR4 and cyclin T1 (red frame).
Additional human specific factors probably exist.
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The hu-PBL-SCID mouse model is based on the intraperi-
toneal injection of human PBL [25] and is susceptible to
HIV infection [26]. However, within days, human PBL in-
jected into mice react against the murine disparity with a
vigorous activation: their proliferation rate increases, and
the CCR5 chemokine receptor and HLA-DR are upregu-
lated [27–29], resulting in xeno-reactive T-cells [30]. Mice
with significant blood T-lymphocyte chimerism suffer from
high levels of graft-versus-host disease (GVHD) and mor-
tality. Mice with no or transient T-cell chimerism have a
low incidence [31]. Use of this model is limited mostly by
the lack of de novo development of continuously differen-
tiating human cells, activation status of the xenoreactive T
cells and the GVHD (table 1).
New approaches for generating humanised mice
In 2004, a novel humanised mouse model was reported. It
was based on transplanting human CD34+ haematopoiet-
ic progenitor cells (CD34+ cells) directly into the liver of
newborn immunodeficient mice (Rag2-/- γc-/-) [32]. By 10
weeks after transplantation, the mice develop a lymphoid
system of human origin with T cells, B cells, NK cells,
monocytes and dendritic cells. Notably, the T cells display
a pattern of naive and memory cells and a Vβ repertoire
similar to that of humans. The mouse mounts a specific an-
tibody response against model antigens, such as pneumo-
coccal and tetanus toxoid antigens, but the response is
much weaker than that in humans (table 1).
This model is a significant step toward humanisation. Im-
portantly, the mice lack the γc chain, which results in even
more drastic immunodeficiency as compared with SCID
mice. The γc chain is an essential component of the IL-2,
-4, -7, -9, - 15 and -21 receptors. Its absence severely com-
promises the development of immune cells, including NK-
cell development, and thus their rejection potential against
transplanted xenogeneic tissue. It also makes the mice less
susceptible to lymphoma development. Indeed, the NOD-
SCID IL-2Rγ-null mice are much more useful than the
NOD-SCID mice for transplanting human tissue [33]. Not-
ably, NOD-SCID IL-2Rγ-null mice show a similar degree
of immunodeficiency as Rag1 or 2-/- γc -/- knock-out mice;
they have been developed by crossing of SCID mice with
non-obese diabetic (NOD) mice and mice deficient in the
gamma c (γc) chain of the IL-2 receptor [34].
Table 1: Compilation of the various humanised mouse models.
Humanised mouse
model
Engraftment Cellular composition in
reconstituted hu mice
Supports HIV
infection with
Advantages Disadvantages
hu-PBL SCID [25] N/A • T and B cells • CCR5 and
CXCR4-tropic
strains§ [26, 28,
62]
• Easy to generate (i.e. good access to
PBLs)
• Can immediately be used after transfer of
PBLs
• No multilineage haematopoiesis
• Limited time frame for experi-
ments [62]
• Strong activation of T-cells [27,
28]
• Emergence of xeno-reactive T-
cells (GvHD) [30]
Thy/Liv SCID hu [23] N/A • T cells
• Single positive
double positive
and double negat-
ive Thymocytes
• CCR5-* and
CXCR4-tropic
strains [24, 58,
59]
• Organoid of foetal thymus/liver tissue with
sustained T-cell lymphopoiesis
• Valuable to study certain pathogenic as-
pects (see text)
• Surgical skills needed
• Human foetal tissue needed
• No multilineage haematopoiesis
• Sampling mainly restricted to the
organoid since lack of solid peri-
pheral reconstitution
• Lack of CCR5 expression on in-
trathymic T progenitor cells
Rag2-/- γc -/-[32] ++ • T and B cells
• Monocytes
• Macrophages
• NK cells
• DCs
• CCR5- and
CXCR4-tropic
strains [68, 69,
71]
• Long-term multilineage haematopoiesis
• Specific antibody response to recall anti-
gens [32]
• Suited to study HIV pathogenesis [118,
131, 132], HIV latency [90], gene therapy
and novel anti-HIV treatment approaches
[90]
• Delay between transplantation of
human CD34+ cells and develop-
ment of lymphoid system of ~15
weeks.
NOG [38] or NSG [33] +++ • T and B cells
• Monocytes
• Macrophage
• NK cells
• DCs
• CCR5- and
CXCR4-tropic
strains [40, 70,
131, 132]
• Higher reconstitution levels as compared
to Rag mice [39, 41]
• Suited for studying HIV pathogenesis
[119, 123], HIV treatment [95, 98] and
latency and gene therapy approaches
[102, 107]
• Sensitive to irradiation
NOD/SCID ¶
-hu BLT [42]
And
NOD/SCID γc -/- (NSG)
BLT [133]
+++ • T and B cells
• Monocytes
• Macrophages
• NK cells
• DCs
• CCR5- and
CXCR4-tropic
strains [43, 77,
80, 88, 108, 115]
• Generation of adaptive immune re-
sponses [115]
• Suited for studying HIV pathogenesis [43,
115], anti-HIV treatment [77, 80, 108], HIV
latency [88] as well as novel gene ther-
apies
• Two step procedure for generat-
ing BLT mice
• Surgical skills needed
• Human foetal tissue needed
N/A = not applicable
+ = good engraftment
++ = high engraftment
+++ = very high engraftment
§ Infection using CXCR4 tropic HIV-1 strains only successful shortly after transfer of human PBLs.
* Controversial data concerning the permissiveness of foetal thy/liv SCID mice to infection with CCR5 tropic HIV-1 strains.
¶ For simplicity reasons, we put together these two subtly different models; in fact, BLT mouse using NSG background show a superior engraftment as compared to NOD/
SCID BLT mice.
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Modifications for improving the engraftment of human
haemato-lymphopoietic tissue have been investigated, in-
cluding the use of human foetal liver derived CD34+ cells,
cultivating the CD34+ cells with a cytokine cocktail before
transplantation [35], pre-conditioning the mice with bu-
sulfan instead of irradiation [36, 37], the use of different
mouse strains, such as NOD/shi-scid/γcnull (NOG) [38] or
NOD/SCID/γc -/- (NSG) mice [39], the transplantation of
CD34+ cells intravenously or into the bone marrow or the
transplantation of CD34+ cells at older age of the mice
[39]. (NSG and NOG mice are nearly identical except for
the modification of the γc chain receptor; in both strains,
triggering through the γc chain receptor is disabled: in NSG
mice the receptor is completely knocked down, and in
NOG mice the intracytoplasmic tail is truncated). NOG
mice are especially vulnerable to developing lymphomas
after irradiation; however, they yield similar engraftment
results even when not irradiated [40]. Very importantly,
the lifespans of humanised mice, except of irradiated NOG
mice, appear to be similar to those of wildtype mice; the
mice eventually die due to infirmity. NSG mice trans-
planted at birth with haematopoietic progenitor cells either
from human foetal liver or from human cord blood gave
the better engraftment than the Balb/c-Rag1-/- and
C.B-17-scid/bg mice [41]. Similar data have been reported
by Brehm et al. [39].
The BLT mouse deserves special mention [42]. BLT is
an acronym for bone marrow liver thymic. In this model,
foetal liver/thymus is placed under the renal capsule in
6–8-week-old immunodeficient mice as with standard
SCID-hu mice. However, after 3 weeks, the mice are sub-
lethally irradiated, and autologous human CD34+ cells are
transplanted into the mice. These cells home to the bone
marrow and also migrate to the scaffold generated by the
initial transplantation of the human foetal liver/thymus tis-
sue. In the BLT mice, engraftment of human lymphoid tis-
sue is highly efficient, even to the gastro-intestinal tract
[43]. The innate and adaptive immune responses appear to
be generally more complete in the BLT mice than in hu-
manised mice generated by transplanting human CD34+
cells alone [42]: BLT mice generate a human MHC-restric-
ted T-cell response to Epstein Barr virus (EBV) and ac-
tivated Vβ2-TCR+ T-cells when dendritic cells present the
superantigen toxic shock syndrome toxin 1 (TSST-1). Not-
ably, TSST-1 specifically activates and induces the TCR
Vβ2+ cells to proliferate. Generating an adaptive immune
response is facilitated by educating the human T-cells in
an autologous thymic microenvironment. This is not the
case in the other humanised mouse models, which have
xenogeneic mouse thymic environments. To overcome this
limitation, immunodeficient mice were generated express-
ing the human HLA class I genes [44]. Here, mice trans-
planted with HLA-matched cord blood cells supported the
in vivo differentiation of functionally mature human cyto-
toxic lymphocytes associated with a wide spectrum of
functional human T-cell subsets. The mice mounted an
EBV-specific immune response upon challenge as quanti-
fied by tetramer staining and enzyme-linked immunospot
(ELISPOT) assay.
Thus, introducing human HLA-class I transgenes signific-
antly improved the humanisation of the mice. Similarly, a
new report demonstrated expression of class II (HLA-DR4)
in NOD- Rag1 -/- /γc -/- mice and consequent improvement
in T- and B-cell development and function [45]. Additional
human transgenes critical for haematopoiesis have been in-
troduced into the mouse strain backgrounds, and this action
should result in a lymphoid system that even more closely
approximates the human lymphoid system.
Humanised mice have also been used to study (1.) haema-
topoietic development, (2.) a variety of microorganisms,
including EBV [42, 46], herpes simplex virus [47], Dengue
fever [48, 49], influenza [50] and Salmonella typhi [51, 52],
(3.) sepsis [53] and iv) virus-induced tumours [54, 55].
Irrespective of the strain, immunodeficient mice are prone
to opportunistic infections and must be kept in optimized
hygienic animal care facilities. Whether the humanisation
protects mice from infections is not known.
Humanised mice for studying HIV
infections
The hu-PBL SCID and foetal liv/thy SCID hu mouse mod-
els have been valuable for the study of HIV infection, in-
cluding immune responses (e.g., the effect of vaccination
with vaccinia gp160 and recombinant gp160 [56]), in vivo
drug testing [57–59], anti-HIV effects of CD8+ cytotoxic
T-cells [60] and neutralising antibodies [61], virulence of
HIV isolates [62], and the significance of distinct HIV ac-
cessory proteins on virulence [63, 64], and viral latency
[65]. However, these models have several limitations. Most
importantly, they lack multilineage haematopoiesis and the
capacity to generate an effective human immune response
(table 1).
The “new generation” of humanised mice has a number
of positive aspects, such as multilineage haematopoiesis,
no or very rarely graft-vs-host disease, a longer lifespan of
the mice, and the generation of some immune responses
(table 1). In the next sections, we will focus exclusively
on these new humanised mouse models. Reviews compar-
ing the properties of the various humanised mouse models
based on the use of either Rag, NSG or NOG mouse strains
have recently been published [66, 67]. In this review, we
focused primarily on the overall value of humanised mice
for studying HIV infection and specified only the mouse
strain used when clear differences were described as related
to HIV infection or pathogenesis.
Humanised mice support high-level viraemia
The new humanised mice support high levels of HIV in-
fection with either CCR5- or CXCR4-tropic strains [36,
68–71]. Plasma HIV RNA copy numbers of 104–105/ml in
those mice are similar to the levels found in HIV-infected
humans (note, that HIV replication can be easily monitored
by repetitive sampling of peripheral blood). HIV-infected
cells were detected in the spleen, lymph nodes, thymus
and lungs, indicating dissemination of the virus. Unlike hu-
PBL SCID mice, humanised mice sustain high-level viral
replication for more than a year [35]. Depending on the vir-
ulence of the HIV strain used, the mice show distinct CD4+
T-cell depletion rates over time. Initial reports noted either
very limited or no HIV-specific humoral immune responses
[68, 70]. Importantly, expression of the HIV co-receptors
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CXCR4 and CCR5 on engrafted and differentiated human
immune cells was similar to that seen in humans [68, 70,
71]. Co-receptor expression in human CD4+ T cells is the
major determinant of HIV tropism in vivo [72]. Indeed, as
seen in HIV-infected human, disseminated infection in hu-
manised mice with CCR5-tropic stains leads preferentially
to infection and depletion of CD4+ memory T lymphocytes
[73]. CCR5 is expressed mainly on memory T lymphocytes
and is absent from naive T cells.
Humanised mice for studying sexual transmission and
its prevention
A prerequisite for studying HIV sexual transmission in hu-
manised mice is the engraftment of the female reproductive
tract and/or the gastro-intestinal tract with virus suscept-
ible human cells. Both humanised Rag1-/-γc-/- mice and
Rag2-/-γc -/- mice, as well as BLT mice, are well engraf-
ted with human cells in the vagina [74–77], and vaginal
HIV transmission is efficient in all these three new mouse
models. Like the human gut, the mouse small intestines
include abundant Peyer’s patches and the large intestines
are populated with lymphoid follicular aggregates with hu-
man T and B lymphocytes, macrophages and DC [43, 74].
Here, memory T cells with prominent expression of CCR5
are permissive to CCR5-tropic strains. BLT mice also show
human CD4CD8αα cells, a T-cell subset present only in the
gut-associated lymphoid tissue [77]. These mice respond
with disseminated HIV infection subsequent to either rectal
or vaginal infection with cell-free HIV [43, 74, 75, 77].
However, efficient engraftment of the gastrointestinal tract
of Rag2-/-γc-/- mice with human cells appears to depend on
the protocol used: mice transplanted with CD34+ cells de-
rived from human foetal liver and cultured overnight with
IL-3, IL-6 and stem cell factor showed human cell engraft-
ment in the gut [74]. This is not the case in mice trans-
planted with uncultured CD34+ cells derived from cord
blood [78]. The latter also differed in their susceptibility to
rectal HIV challenge [74, 78].
Humanised mice represent a very significant advancement
for evaluating novel microbicides for preventing HIV in-
fection and very nicely complement the much more ex-
pensive monkey models. Indeed, several recent studies
demonstrated the utility of these models for testing oral and
topical pre-exposure prophylaxis strategies with different
anti-HIV drugs (e.g., Tenofovir, Maraviroc, Raltegravir)
currently on the market [77, 79–82] or with compounds
in development [83]. In particular, topical application of
the CCR5 antagonist Maraviroc formulated as a gel pre-
vented HIV vaginal transmission [81], and the novel CD4
aptamer-siRNA chimeras [83] showed partial protection.
Studies of anti-retroviral treatment strategies
A few reports have noted the utility of the new humanised
mice for evaluating antiretroviral therapies [84–89]. We
made a major effort for defining a gold standard for ART
in humanised mice by first examining the pharmacokinetic
of a number of anti-retroviral compounds [90]. In this work
we showed efficacious anti-retroviral treatment when the
anti-retroviral compounds were added to food pellets or
when long-acting drugs were used [90]. We also demon-
strated emergence of resistance in insufficiently treated
mice, and viral rebound from previously undetectable
levels after cART interruption, confirming a latent reser-
voir as reported recently [85, 86, 88, 91]. Thus, humanised
mice represent a highly valuable model for pre-clinical
proof-of-concept studies to evaluate novel anti-retroviral
compounds and to study latency that closely approximates
the status of HIV-infected humans treated with cART.
Several studies also evaluated novel molecules for sup-
pressing HIV in vivo in these new mouse models [89,
92–98]. They involved studies investigating the potential of
Tat peptide analogues for inhibiting HIV replication (89) as
Box
Human host
factors
Definition Function
CD4 Cluster of differentiation 4 HIV binding-entry receptor, expressed in T-helper cells, macrophages/
monocytes and dendritic cells
CCR5 C-C motif-chemokine receptor 5 Transmembrane chemokine receptor, important for cytoskeletal reorganisation
and cell motility, HIV co-receptor
CXCR4 CXC motif-chemokine receptor 4 Transmembrane chemokine receptor, chemotactic activity for lymphocytes, HIV
co-receptor
Cyclin CDK9 Cyclin dependent kinase 9 Cell-cycle regulator, binds Tat and cyclin T1, required for RNA polymerase II
transcriptional elongation of HIV
Mouse strains Definition Description
C.B.-17 SCID/
SCID
Severe combined immunodeficiency (SCID) Mutation in the Prkd gene (lack of B and T cells)
human-PBL-
SCID
PBL: peripheral blood leucocytes Intraperitoneal injection of human PBL into SCID mouse
Rag1-/- γc-/-
Rag2-/- γc-/-
Deficiency in the recombinase activating gene 1 or 2 and the common
γ chain of the IL-2 receptor
Lack of B, T and NK cells
NOD Non-obese diabetic mouse Reduction of NK cell activity
NOD/SCID NOD and SCID mouse Lack of B and T cells and NK cell activity
NSG (NOD/
SCID/γc-/-)
NOD/SCID mice with entire knock-out of the common γc chain
receptor
Lack of B, T and NK cells and block of the maturation and activity of these cells
NOG (NOD/
SCID/γc-/-)
NOD/SCID mice with knockout of the intracytoplasmatic tail of the
common γc receptor
Lack of B, T and NK cells and block of the maturation and activity of these cells
BLT Bone marrow, liver, thymus NOD/SCID or NOD/SCID/γc-/- mice transplanted with foetal liver, thymus and
CD34+ cells
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well as the effects of silencing (si)RNAs directed against
viral proteins (e.g., Tat, Rev, Vif) or CCR5 that were de-
livered either by aptamers binding to the HIV envelope gly-
coprotein [92], dendrimer nanoparticles [93], single-chain
antibodies binding to CD7 [95] or by immunoliposomes
targeting the lymphocyte function-associated antigen-1
(LFA-1) [94]. The gp-120-binding aptamers targeted pro-
ductively infected T cells specifically, and the single-chain
antibodies and immunoliposomes targeted the white blood
cells independently of HIV infection. In all of these in vivo
studies, HIV replication was significantly suppressed. The
humanised mice are also useful for studying the protect-
ive effect of distinct broadly neutralising antibodies de-
livered either by antibody-expressing cells administered as
“backpacks” [96] or by adeno-associated virus-based vec-
tors [97].
Studying gene therapeutic approaches for HIV/AIDS
Humanised mice represent a unique option to explore
haematopoietic stem cell–based gene therapy strategies.
Gene manipulation of human CD34+ cells to modulate host
factors is also very attractive for HIV pathogenesis studies.
Immunodeficient mice have long been used to assess the
ability of gene-transduced human CD34+ cells to differen-
tiate into various cellular subsets. In 1994, retroviral vec-
tor–transduced human CD34 cells were shown to differ-
entiate into mature T-cell subsets in SCID-hu grafts [99].
Later, long-term engraftment of human CD34+ cells trans-
duced with an HIV vector was demonstrated in NOD/SCID
mice; 4–10% of the human cells were transduced [100].
NOD/SCID and the NSG mice seem to engraft similar
numbers of transduced human CD34+ cells [101].
However, when using bone marrow from those mice for
secondary reconstitutions in mice on the same background,
human tissue from NSG mice engrafted far better than that
from NOD/SCID mice, pointing to increased numbers of
long-term SCID repopulating cells. These features are fa-
vourable for studying long-term transgene expression and
the analysis of retroviral-insertion sites in primary and sec-
ondary transplanted NSG mice.
These findings, along with the higher levels of human tis-
sue engraftment, suggest that the “novel generation” of hu-
manised mice will be very useful for studying gene therapy
approaches and examining distinct genes for their patho-
genic effects in various settings. In addition, zinc-finger
nuclease–mediated gene engineering is another very prom-
ising gene-engineering technology that has been explored
in these mouse models [102].
A vast body of literature describes various approaches to
control HIV by ex vivo gene therapy [103, 104]. Gene ther-
apy approaches for HIV/AIDS i) target host factors critic-
al for HIV replication or ii) HIV genes mandatory for HIV
replication (e.g., Nef) [105], iii) introduce novel gene con-
structs (e.g., Trim5-cyclophilin fusion protein that inhib-
its HIV replication) [106], or iv) employ a broadly neut-
ralising anti-HIV antibody [107]. The value of humanised
mice for studying genetically altered human CD34+ cells
to treat HIV is nicely illustrated by several studies, such
as those targeting CCR5 with siRNA- or shRNA-mediated
silencing [108, 109] or by zinc finger–mediated excision
[102]. Notably, the HIV receptor complex consists of CD4
and either the HIV co-receptor, CCR5 or CXCR4 [72].
CCR5-tropic strains are transmitted and predominate un-
til late-stage disease [110]. CXCR4-tropic strains emerge
in advanced stages of HIV disease in about 50% of HIV-
infected patients and seem to accelerate the immune de-
ficiency [111]. Silencing CCR5 has been mentioned as a
potential “cure” for HIV. A recent report described an HIV-
infected patient who suffered from acute myeloid leuk-
aemia and who was transplanted with human CD34+ stem
cells lacking CCR5. Strikingly, the patient appears to be
fully cured since HIV did not rebound subsequent to inter-
ruption of cART [112]. While it involved only a single pa-
tient, this report gives credence to genetic approaches tar-
geting CCR5.
Introducing a lentiviral construct silencing CCR5 into hu-
man CD34+ cells resulted in a clear reduction of CCR5 on
the target cells of HIV in vivo [108]. The engineered pro-
genitor cells showed long-term haematopoietic repopulat-
ing capacity by secondary transplantation. Notably, the ge-
netically engineered progeny cells behaved identically as
the controls. In vitro the engineered cells were resistant
to HIV infection with CCR5-tropic strains. Zinc fin-
ger–mediated excision of CCR5 in CD34+ cells resulted in
progeny cells lacking CCR5, and the mice showed lower
HIV replication and prevention of CD4+ T-cell loss in vivo,
as compared to control mice [102]. Very importantly, HIV
infection resulted in a selection of cells resistant to HIV
over time. This technology demonstrated cells with long-
term haematopoietic repopulation capacity. Other genetic
approaches have focused on T cells and engineered HIV-
resistant CD4+ T cells with CXCR4-specific zinc finger
nucleases [113].
These studies clearly indicate that humanised mice are a
very promising tool for exploring gene engineering ap-
proaches to treat and/or cure HIV. The major hurdles will
not be the identification of targets rendering cells resistant
to HIV but to achieve sufficiently high numbers of genet-
ically engineered CD34+ cells, the migration of transduced
cells to the niches of haematopoietic stem cells, preventing
the insertional risk favouring neoplastic transformation or
off-target effects (e.g., activation of the innate immune re-
sponse). Here, too, the humanised mouse model will be a
versatile tool for exploring these questions.
Humanised mice for generating an HIV-specific
immune response
Inducing a robust HIV-specific immune response was re-
ported in NSG mice reconstituted with human CD34+ cells
from newborns [114] and in the BLT mouse model [115].
Both papers reported HIV-specific CD4+ and CD8+ T-cell
responses with overlapping HIV peptide pools [114, 115]
or ELISPOT assays [115]. The relevance of the CD8+ T
cells in constraining HIV replication in humanised mice
was illustrated by a significantly higher replication rate
when CD8+ T cells were depleted [114]. The humanised
mice also developed humoral immune responses against
HIV [115]. However, antigen-specific immune responses
in humanised mice seem to take longer to develop than
in adult humans infected with HIV, possibly reflecting the
lack of full maturity of the human immune systems of these
mice after reconstitution [115]. In previous work, such sol-
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id HIV-specific antibody immune responses were not re-
ported. The analysis might have been performed too soon
after HIV infection. In view of limited number of studies,
we still do not know if the current generation of human-
ised mice is suited for studying antigen-specific immune
responses and, in particular, vaccine approaches. In mice
reconstituted directly with human CD34+ cells the selec-
tion of T cells is done by murine thymic stromal cells. The
subsequent generation of an antigen-specific immune re-
sponse, however, is based on the processing of antigens
by human antigen-presenting cells in the humanised mouse
model and therefore might be suboptimal.
HIV evolution over time
HIV’s diversity is one of its main features. It is also a key
element for immune escape and emergence of resistance
to ART. HIV’s diversity is due to the inaccuracy of the
HIV reverse transcriptase, hyperamination of the nascent
DNA strand during reverse transcription by the members
of the APOBEC family, and recombination events between
distinct HIV strains. Indeed, the genotypic and phenotypic
changes in the viral envelope gene in humanised mice in-
fected with a distinct HIV strain, JR-CSF, showed the mean
rate of divergence of viral populations over 44 weeks sim-
ilar to that in humans [116]. They noted a disproportionate
number of guanosine-to-adenosine transitions in the HIV
envelope, indicating that APOBEC3G is active in this mod-
el. Furthermore, a number of substitutions in the envelope
gene were identified.
HIV immune activation and dysfunction
Sustained immune activation is the major trigger of HIV-
associated immunodeficiency. Various mechanisms, such
as disruption of the gastrointestinal tract barrier during
acute HIV infection [117] or various HIV accessory gene
products, may contribute to the HIV-associated immune ac-
tivation [18]. Immune activation is also observed on the
CD4+ and CD8+ T cells in HIV-infected humanised mice
[115, 118]. We used the humanised mice to study the role
of macrophages in immune activation [118]. We found that
HIV infection results in a disturbed phagocytosis by mac-
rophages. Notably, macrophages are essential for clearing
bacterial products. We concluded that disruptions of the
gastrointestinal tract barrier, together with the macrophage
dysfunction, are a main element of higher blood levels of
bacterial products and thus in HIV-associated immune ac-
tivation.
Immune activation affects also the PDL1-PD1 axis (PDL =
programmed death ligand). The inhibitory receptor PD-1,
which indicates exhaustion of T cells, was increased on the
T cells in HIV-infected humanised mice, reminiscent of the
findings in humans [115]. Ongoing studies are examining
the benefits of blocking the PD-1 pathway.
The presence of various immune cells, such as plasmacyt-
oid dendritic cells (pDC) and T-regulatory cells, in human-
ised mice presents a unique opportunity to assess their ef-
fects on HIV infection and vice-versa (i.e., HIV’s effect
on them). For example, rapid infection and activation of
pDCs were seen in HIV-challenged humanised mice [119].
Their activation correlated with activation of CD4+ T cells
and their apoptosis. While CD4+ T cells were depleted,
pDCs were maintained but functionally impaired. The pres-
ence of T-regulatory cells in these mice may help to dissect
their role in HIV infection. These cells are preferentially
targeted by HIV during acute HIV infection in these mice
[120].
CNS invasion by HIV
AIDS-related dementia occurs in about 30% of HIV-infec-
ted patients with advanced immunodeficiency [121]. AIDS
dementia is characterised by the immigration of macro-
phages, formation of microglial nodules, and generation of
multi-nucleated giant cells, most likely due to viral induced
fusion between microglial cells and/or macrophages. HIV-
infected humanised mice show pathologic anomalies in the
brain reminiscent of those in HIV-infected patients with
AIDS dementia. In particular, activated human blood-borne
macrophages migrate into the brain. Human cells enter into
the brains more quickly in HIV-infected mice than in con-
trol mice. Productively infected macrophages and cells of
lymphocyte morphology are found in the meninges and
perivascular spaces [122]. Strikingly, CD8+ T-cell deple-
tion aggravated the pathological findings, suggesting that
CD8+ T cells could subdue HIV infection to some extent.
Using advanced neuroimaging and post-mortem examin-
ation, HIV-infected mice show a loss of neuronal integ-
rity [123]. These data are encouraging: humanised mice
represent a valuable tool for examining mechanistic and
therapeutic aspects of HIV-associated dementia. However,
as reiterated by the study authors, additional studies are
needed for a more detailed characterisation and validation
of the neuronal damage associated with HIV infection in
this mouse model [124].
Future generations of humanised mice
Despite the advances made in humanised murine models,
the reconstituted lymphoid system still lacks a well-elab-
orated lymphoid architecture. This is partially explained
by the lack of human cytokines critical for haematopoiesis
and/or by insufficient interactions between cells of the mur-
ine stroma and human haematopoietic cells. The less than
optimal lymphoid architecture and the education/selection
of T-cells on a murine thymic scaffold result in a rather
modest adaptive immune response. As outlined above,
transplantation of HLA-matched cord blood into a mouse
strain transgenic for human HLA gives more robust specif-
ic T-cell response. To improve the humanisation of mice,
additional human transgenes critical for haematopoiesis are
introduced into mice.
The knock-in of human thrombopoietin (TPO) into Rag2-/-
γ c-/-, which is essential for the expansion and maintenance
of HSC [125], resulted in a higher level of engraftment and
an increase in the breadth of multilineage haematopoiesis
with higher number of myeloid cells than in control mice
expressing the murine TPO [126].
Other knock-in (KI) genes examined for improving the
humanisation were human IL-3 in concert with human
granulocyte macrophage cytokine stimulating factor (GM-
CSF) [127] and colony stimulating factor-1 (CSF-1) [128].
In IL-3/GM-CSF KI mice, transplantation of human pre-
genitor cells resulted in a more pronounced inflammatory
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reaction in response to intraperitoneal administration of
lipopolysaccharide than in controls. In addition, IL-3/GM-
CSF KI mice had improved human myeloid immune re-
constitution in the lung as exemplified by the presence
of alveolar macrophages; the human alveolar macrophages
mounted an innate immune response when challenged with
influenza virus but could not control it. This model might
be especially good for studying pulmonary diseases [127].
The knock-in of CFS-1 enhanced the differentiation of my-
eloid cells into monocytes and macrophages [128].
As outlined above, differences in the extent the various
mouse backgrounds support human cell engraftment exist.
Positional cloning identified alleles of the inhibitory re-
ceptor signal regulatory protein alpha (SIRPα) as a reason
for the difference of engraftment levels between mouse
strains [129]. In NOD mice, which have higher engraft-
ment levels than other mice, SIRPα on murine macro-
phages showed enhanced binding to the human CD47 lig-
and. This enhanced binding inhibits phagocytosis of the
xenograft and secretion of TNF-α by macrophages. Trans-
genic expression of SIRPα in Rag2-/-γc-/- increased the en-
graftment level of HSC to a level similar to NSG mice and
improved the functionality of the immune system [130].
These next-generation mice will most likely become im-
portant assets for the research community. Furthermore,
the step-wise progress made in humanisation methods will
continue and will create an array of humanised mouse mod-
els appropriately suited to address specific research ques-
tions.
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Figures (large format)
Figure 1
HIV-1 needs critical host factors for efficient replication. HIV binds to the HIV receptor complex of the human CD4 cell-surface molecule and a
co-receptor, either CCR5 or CXCR4, via the HIV envelope glycoprotein 120 (HIV env gp120). After conformational changes in the HIV env gp41,
viral host cell membrane fusion occurs (2). The next steps are the decapsidation (3) and release of the HIV RNA from the virus particle. Reverse
transcription generates a viral complementary DNA (cDNA) based on the viral RNA template and using HIV’s own reverse transcriptase (4).
Once the cDNA is generated, the preintegration complex (PIC) is assembled, nuclear trafficking and integration of the viral cDNA into the host
genomic DNA follow (5). Efficient transcription and elongation require formation of P-TEFb (positive transcription elongation factor b) consisting
of Tat (6A), human cyclin-dependent kinase 9 (CDK-9) (6B) and cyclin T1 (6C), which binds to the nascent HIV transcripts. Fully or partially
spliced HIV mRNA (7) is used to translate viral proteins. Unspliced HIV RNA is packaged into newly generated virions. Assembly of HIV proteins
and RNA and budding take place at the cellular membrane (9). HIV release is inhibited by murine tetherin at the cellular membrane because
murine tetherin is insensitive to the viral protein Vpu, which inhibits human tetherin by directing its proteasomal degradation (blue frame).
Human host factors critical for HIV replication are CD4, CCR5, CXCR4 and cyclin T1 (red frame). Additional human specific factors probably
exist.
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